Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 8, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...

Company Deals

Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China

Fineline Cube Apr 8, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...

Company Drug

Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024

Fineline Cube Apr 8, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base

Fineline Cube Apr 8, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...

Company Deals

Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation

Fineline Cube Apr 8, 2024

Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...

Company Drug

Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere

Fineline Cube Apr 8, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Drug

Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients

Fineline Cube Apr 8, 2024

Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...

Company Drug

Junshi Biosciences’ Toripalimab Approved for First-Line RCC Treatment in China

Fineline Cube Apr 8, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has received a new indication approval...

Company Drug

Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis

Fineline Cube Apr 7, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II...

Company Drug

IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis

Fineline Cube Apr 7, 2024

China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...

Company Drug

Ipsen Secures NMPA Approval for Somatuline in Advanced Neuroendocrine Tumors

Fineline Cube Apr 7, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a France-based biopharmaceutical company, has received new indication approval from...

Company Drug

Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment

Fineline Cube Apr 7, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...

Company Deals

Siemens Healthineers and Siemens China Partner with Fudan Hospital Logistic Service on Green Imaging Centers

Fineline Cube Apr 7, 2024

Germany-based Siemens Healthineers AG, along with its subsidiary Siemens China, has entered into a strategic...

Posts pagination

1 … 378 379 380 … 666

Recent updates

  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
  • China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Company

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.